Compare TARA & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TARA | BDSX |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.1M | 276.2M |
| IPO Year | 2014 | 2020 |
| Metric | TARA | BDSX |
|---|---|---|
| Price | $3.89 | $26.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $24.40 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 313.1K | 115.9K |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.25 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,948,000.00 | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $3.02 | $0.35 |
| 52 Week High | $7.82 | $31.31 |
| Indicator | TARA | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 52.61 |
| Support Level | $3.73 | $22.99 |
| Resistance Level | $4.17 | $31.31 |
| Average True Range (ATR) | 0.14 | 2.29 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 17.91 | 28.40 |
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.